STIM1 and benign prostatic hyperplasia: In agreement with these results obtained by immunohistochemistry on patient samples, STIM1 expression was reduced in carcinoma cell lines relative to the benign prostate hyperplasia (BPH) cell line BPH-1, and additionally reduced in the malignant PC3 line relative to the less metastatic DU145.